C4 Therapeutics (CCCC) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Net Income towards Common Stockholders Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -12.04% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 95.87% |
| 10 | C4 Therapeutics | 499.92 Mn | 246.25 Mn | - | 9.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.17% |
| Mar 31, 2026 | 4.53% |
| Dec 31, 2025 | 41.10% |
| Sep 30, 2025 | -30.41% |
| Jun 30, 2025 | -46.87% |
| Mar 31, 2025 | 7.19% |
| Dec 31, 2024 | 0.52% |
| Sep 30, 2024 | 8.77% |
| Jun 30, 2024 | 50.68% |
| Mar 31, 2024 | 18.46% |
| Dec 31, 2023 | 6.54% |
| Sep 30, 2023 | 15.40% |
| Jun 30, 2023 | -33.65% |
| Mar 31, 2023 | -9.99% |
| Dec 31, 2022 | -137.48% |
| Sep 30, 2022 | -29.47% |
| Jun 30, 2022 | -19.03% |
| Mar 31, 2022 | -50.78% |
| Dec 31, 2021 | -36.97% |
| Sep 30, 2021 | 8.74% |